Altimmune (ALT) Retained Earnings (2010 - 2026)

Altimmune (ALT) has reported Retained Earnings for 17 consecutive years, with -$5.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 99.1% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$5.2 million (up 99.1% YoY), while the FY2025 annual figure was -$4.9 million, up 0.9% from the prior year.
• Retained Earnings declined to -$5.2 million in Q1 2026 per ALT's latest filing, from -$4.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $676.4 million in Q3 2024 and bottomed at -$581.0 million in Q1 2025.
• Historically, Retained Earnings has averaged $94.5 million across 5 years, with a median of -$5.0 million in 2025.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 6103.16% — and 2024, when it surged 13211.47%.
• Altimmune's Retained Earnings stood at $568.4 million in 2022, then sank by 182.04% to -$466.3 million in 2023, then jumped by 98.93% to -$5.0 million in 2024, then gained by 0.9% to -$4.9 million in 2025, then declined by 6.01% to -$5.2 million in 2026.
• Business Quant data shows ALT's Retained Earnings at -$5.2 million in Q1 2026, -$4.9 million in Q4 2025, and -$5.0 million in Q3 2025.